GlassScriptPhysician profile
Brenna A Labere
NPI 1952834368
$1,167.55
in general payments reported to CMS, 2019-2025
16 companies · $589 in 2025
The $589 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $210 · 2024: $369 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,096 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,095.55 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $209.33 | 2023-2025 | Cuvitru, Takhzyro |
| Csl Behring | $137.73 | 2025 | Hizentra, Haegarda |
| Genzyme Corporation | $128.68 | 2024-2025 | |
| Pharming Healthcare, INC. | $117.04 | 2024 | Ruconest |
| Glaxosmithkline, LLC. | $72.20 | 2023-2025 | Nucala |
| Sanofi-Aventis U.S. LLC | $72.00 | 2024 | |
| Sobi, INC | $62.64 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $61.59 | 2025 | |
| Kaleo, INC. | $60.30 | 2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $55.30 | 2025 | Neffy |
| Horizon Therapeutics Plc | $47.18 | 2023 | Actimmune |
| Biocryst US Sales Co., LLC | $40.32 | 2024-2025 | Orladeyo |
| Amgen INC. | $29.92 | 2025 | Actimmune |
| Galderma Laboratories, L.P. | $26.01 | 2025 | Nemluvio |
| Incyte Corporation | $24.05 | 2025 | Opzelura |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greer Laboratories, INC. | $23.26 | 2025 | Palforzia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenna Labere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.